Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Mystery Of Russia’s COVID-19 Vaccine

Reports Differ Over Immunization Program & Manufacturing

Executive Summary

Russia may have approved the first COVID-19 vaccine, but there is uncertainty over when immunization will begin, who will receive it first, and whether the Russian authorities are planning to carry out Phase III trials. 

You may also be interested in...



Coronavirus Notebook: EU Joins COVAX, Sanofi/GSK Vaccine Moves To Phase I/II

Convalescent plasma has taken another battering as a potential treatment for coronavirus patients, after a UK drug safety body agreed with a US expert panel that there was not yet enough evidence to recommend its use in COVID-19 patients. 

Coronavirus Notebook: UK Ups Vaccine Efforts & Calls For More Candidate Therapies

The UK has been stepping up its COVID-19 activity in recent days, ordering more vaccines, encouraging more volunteers to join clinical trials, and expanding its RECOVERY platform for potential new coronavirus therapies. But the government's sudden decision to replace Public Health England with a new institute has raised some concerns within the biopharma industry.

‘No Turning Back’ On Regulatory Changes at UK MHRA

The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel